
    
      The total study duration for each participant was between approximately 29 and maximum of 30
      weeks, consisting of a screening period of 5 weeks and optional up to 7 additional days, a
      treatment period of 12 weeks, and a post-treatment period of 12 weeks.

      Participants who completed the treatment period could be eligible to participate in an
      open-label extension study.
    
  